Denosumab-a new option for solid tumors metastatic to bone

被引：2

作者：

Saylor, Philip J. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2011年 / 8卷 / 06期

关键词：

MULTIPLE-MYELOMA; ZOLEDRONIC ACID; BREAST-CANCER; LIGAND;

D O I：

10.1038/nrclinonc.2011.70

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Zoledronic acid is a potent bisphosphonate used as the standard therapy for the prevention of skeletal-related events in patients with solid tumors metastatic to bone. Three phase III studies have reported head-to-head comparisons of zoledronic acid with denosumab, an inhibitor of the RANK signaling pathway.

引用

页码：322 / 324

页数：4

共 10 条

[1]

*AMG, 2010, XGEV DEN FULL PRESCR

[2] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].

Body, JJ ;

Facon, T ;

Coleman, RE ;

Lipton, A ;

Geurs, F ;

Fan, M ;

Holloway, D ;

Peterson, MC ;

Bekker, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228

[3] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].

Fizazi, Karim ;

Carducci, Michael ;

Smith, Matthew ;

Damiao, Ronaldo ;

Brown, Janet ;

Karsh, Lawrence ;

Milecki, Piotr ;

Shore, Neal ;

Rader, Michael ;

Wang, Huei ;

Jiang, Qi ;

Tadros, Sylvia ;

Dansey, Roger ;

Goessl, Carsten .

LANCET, 2011, 377 (9768) :813-822

[4] Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma [J].

Henry, David H. ;

Costa, Luis ;

Goldwasser, Francois ;

Hirsh, Vera ;

Hungria, Vania ;

Prausova, Jana ;

Scagliotti, Giorgio Vittorio ;

Sleeboom, Harm ;

Spencer, Andrew ;

Vadhan-Raj, Saroj ;

von Moos, Roger ;

Willenbacher, Wolfgang ;

Woll, Penella J. ;

Wang, Jianming ;

Jiang, Qi ;

Jun, Susie ;

Dansey, Roger ;

Yeh, Howard .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1125-1132

[5]

HOFF AO, J BONE MINER RES, V23, P826

[6] RANK ligand as a therapeutic target for bone metastases and multiple myeloma [J].

Roodman, G. David ;

Dougall, William C. .

CANCER TREATMENT REVIEWS, 2008, 34 (01) :92-101

[7] Mechanisms of disease: Mechanisms of bone metastasis [J].

Roodman, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1655-1664

[8] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Zheng, M .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :879-882

[9] Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study [J].

Stopeck, Alison T. ;

Lipton, Allan ;

Body, Jean-Jacques ;

Steger, Guenther G. ;

Tonkin, Katia ;

de Boer, Richard H. ;

Lichinitser, Mikhail ;

Fujiwara, Yasuhiro ;

Yardley, Denise A. ;

Viniegra, Maria ;

Fan, Michelle ;

Jiang, Qi ;

Dansey, Roger ;

Jun, Susie ;

Braun, Ada .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (35) :5132-5139

[10] Osteoimmunology: Interplay between the immune system and bone metabolism [J].

Walsh, Matthew C. ;

Kim, Nacksung ;

Kadono, Yuho ;

Rho, Jaerang ;

Lee, Soo Young ;

Lorenzo, Joseph ;

Choi, Yongwon .

ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :33-63

← 1 →